Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
Elise van MulligenAngelique E WeelJ M HazesAnnette H M van der Helm van MilPascal Hendrik Pieter de JongPublished in: Annals of the rheumatic diseases (2020)
The order of tapering did not affect flare rates, DAS or HAQ-DI. DFR was achievable in 15% of patients with established RA, slightly more frequent in patients that first tapered csDMARDs. Because of similar effects from a clinical viewpoint, financial arguments may influence the decision to taper TNF-inhibitors first.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- systemic lupus erythematosus
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- clinical trial
- prognostic factors
- interstitial lung disease
- study protocol
- peritoneal dialysis
- pseudomonas aeruginosa
- healthcare
- biofilm formation
- systemic sclerosis
- decision making
- staphylococcus aureus
- idiopathic pulmonary fibrosis
- candida albicans